Therapeutic Antibodies Against Cancer

被引：61
作者：
Adler, Mark J. [1 ,2 ]
Dimitrov, Dimiter S. [3 ]
机构：
[1] Univ Calif Hlth Syst, Dept Med, UC San Diego Canc Ctr, Encinitas, CA 92024 USA
[2] San Diego Canc Res Inst, Encinitas, CA 92024 USA
[3] NIH, Frederick Natl Labs Canc Res, Frederick, MD 21702 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2012年 / 26卷 / 03期
关键词：
Therapeutics; Antibodies; Cancer; Immunogenicity; Safety; Efficacy; CHRONIC LYMPHOCYTIC-LEUKEMIA; PHASE-III TRIAL; GROWTH-FACTOR RECEPTOR; METASTATIC COLORECTAL-CANCER; CETUXIMAB PLUS IRINOTECAN; PROGRESSION-FREE SURVIVAL; HUMAN MONOCLONAL-ANTIBODIES; BRENTUXIMAB VEDOTIN SGN-35; SQUAMOUS-CELL CARCINOMA; IN-SITU HYBRIDIZATION;
D O I：
10.1016/j.hoc.2012.02.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Antibody-based therapeutics against cancer are highly successful and currently enjoy unprecedented recognition of their potential; 13 monoclonal antibodies (mAbs) have been approved for clinical use in the European Union and in the United States. Bevacizumab, rituximab, and trastuzumab had sales in 2010 of more than $5 billion each. Hundreds of mAbs, including bispecific mAbs and multispecific fusion proteins, mAbs conjugated with small-molecule drugs, and mAbs with optimized pharmacokinetics, are in clinical trials. However, deeper understanding of mechanisms is needed to overcome major problems including resistance to therapy, access to targets, complexity of biological systems, and individual variations.
引用
收藏
页码：447 / +
页数：36
相关论文
共 234 条
[61]   Rituximab-Based Treatments in Waldenstrom's Macroglobulinemia [J].
Dimopoulos, Meletios A. ;
Kastritis, Efstathios ;
Roussou, Maria ;
Eleutherakis-Papaiakovou, Evangelos ;
Migkou, Magdalini ;
Gavriatopoulou, Maria ;
Tassidou, Anna ;
Terpos, Evangelos .
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (01) :59-61
[62]  
Dixit Rakesh, 2009, IDrugs, V12, P103
[63]   Genomic aberrations and survival in chronic lymphocytic leukemia. [J].
Döhner, H ;
Stilgenbauer, S ;
Benner, A ;
Leupolt, E ;
Kröber, A ;
Bullinger, L ;
Döhner, K ;
Bentz, M ;
Lichter, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1910-1916
[64]   Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study [J].
Douillard, Jean-Yves ;
Siena, Salvatore ;
Cassidy, James ;
Tabernero, Josep ;
Burkes, Ronald ;
Barugel, Mario ;
Humblet, Yves ;
Bodoky, Gyoergy ;
Cunningham, David ;
Jassem, Jacek ;
Rivera, Fernando ;
Kocakova, Ilona ;
Ruff, Paul ;
Blasinska-Morawiec, Maria ;
Smakal, Martin ;
Canon, Jean-Luc ;
Rother, Mark ;
Oliner, Kelly S. ;
Wolf, Michael ;
Gansert, Jennifer .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4697-4705
[65]   Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres [J].
Dowsett, M ;
Bartlett, J ;
Ellis, IO ;
Salter, J ;
Hills, M ;
Mallon, E ;
Watters, AD ;
Cooke, T ;
Paish, C ;
Wencyk, PM ;
Pinder, SE .
JOURNAL OF PATHOLOGY, 2003, 199 (04) :418-423
[66]  
Dyer MJS, 1999, SEMIN ONCOL, V26, P52
[67]   Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].
Escudier, Bernard ;
Pluzanska, Anna ;
Koralewski, Piotr ;
Ravaud, Alain ;
Bracarda, Sergio ;
Szczylik, Cezary ;
Chevreau, Christine ;
Filipek, Marek ;
Melichar, Bohuslav ;
Bajetta, Emilio ;
Gorbunova, Vera ;
Bay, Jacques-Olivier ;
Bodrogi, Istvan ;
Jagiello-Gruszfeld, Agnieszka ;
Moore, Nicola .
LANCET, 2007, 370 (9605) :2103-2111
[68]   Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival [J].
Escudier, Bernard ;
Bellmunt, Joaquim ;
Negrier, Sylvie ;
Bajetta, Emilio ;
Melichar, Bohuslav ;
Bracarda, Sergio ;
Ravaud, Alain ;
Golding, Sophie ;
Jethwa, Sangeeta ;
Sneller, Vesna .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2144-2150
[69]   The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review [J].
Eskens, Ferry A. L. M. ;
Verweij, Jaap .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (18) :3127-3139
[70]   Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer [J].
Esteva, FJ ;
Valero, V ;
Booser, D ;
Guerra, LT ;
Murray, JL ;
Pusztai, L ;
Cristofanilli, M ;
Arun, B ;
Esmaeli, B ;
Fritsche, HA ;
Sneige, N ;
Smith, TL ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1800-1808
234567891011